healthcar
personnel
hcp
risk
exposur
variou
pathogen
daili
task
may
serv
reservoir
ongo
nosocomi
transmiss
particularli
highli
contagi
infect
varicella
measl
nosocomi
transmiss
result
infect
suscept
patient
outbreak
work
patient
care
disrupt
increas
cost
occup
exposur
defin
exposur
hcp
materi
contain
infecti
agent
healthcar
set
exposur
occur
inpati
set
eg
patient
room
laboratori
outpati
set
eg
medic
offic
dialysi
unit
nontradit
facil
eg
emerg
medic
skill
nurs
facil
hcp
includ
paid
unpaid
person
work
healthcar
set
potenti
expos
patient
andor
infecti
materi
includ
bodi
substanc
eg
blood
tissu
specif
bodi
fluid
contamin
medic
suppli
equip
contamin
environment
surfac
contamin
air
infecti
organ
transmit
hcp
patient
anoth
hcp
hospit
visitor
environ
sever
rout
tabl
sever
strategi
prevent
infect
among
hcp
includ
vaccin
hcp
risk
infect
close
frequent
contact
highrisk
patient
educ
implement
infect
prevent
control
measur
tabl
time
deliveri
postexposur
prophylaxi
pep
suscept
hcp
event
exposur
pep
involv
administr
antiinfect
agent
vaccin
immunoglobulin
soon
possibl
hcp
potenti
expos
pathogen
order
reduc
risk
infect
manag
hcp
exposur
infecti
agent
paramount
prevent
attenu
infect
hcp
also
prevent
secondari
transmiss
contact
hcp
unprotect
exposur
infecti
sourc
notifi
supervisor
seek
prompt
medic
evalu
infect
control
occup
health
depart
notifi
postexposur
manag
hcp
identif
contact
index
case
applic
immedi
infect
control
measur
index
case
expos
hcp
indic
decid
whether
expos
hcp
continu
provid
patient
care
hcp
evalu
experienc
clinician
occup
health
emerg
depart
per
institut
polici
postexposur
manag
includ
assess
risk
transmiss
thorough
histori
laboratori
test
necessari
follow
indic
time
administr
appropri
pep
avail
gener
psycholog
counsel
expos
hcp
clinician
determin
need
pep
exposur
infecti
agent
base
follow
infect
sourc
patient
materi
time
exposur
extent
type
exposur
suscept
hcp
infecti
diseas
concern
whether
expos
hcp
greater
risk
complic
gener
popul
vaccin
given
expos
hcp
even
present
beyond
time
indic
pep
administr
nonimmun
hcp
vaccin
hepat
b
viru
hbv
season
influenza
measl
mump
rubella
pertussi
varicella
hcp
counsel
risk
infect
acquisit
transmiss
other
particularli
declin
pep
benefit
treatment
import
adher
drug
regimen
possibl
advers
effect
pep
regimen
followup
plan
expos
hcp
counsel
immedi
stop
work
report
work
notifi
infect
control
occup
health
seek
prompt
medic
attent
develop
fever
symptom
sign
infect
concern
compli
work
restrict
exclus
longer
deem
infecti
other
occup
health
depart
healthcar
institut
protocol
avail
hcp
manag
occup
exposur
infecti
diseas
feder
law
requir
cover
employ
ensur
medic
evalu
procedur
vaccin
pep
made
avail
employe
within
reason
timefram
reason
locat
cost
employe
employ
respons
establish
implement
polici
protect
confidenti
expos
employe
sourc
follow
section
review
postexposur
manag
common
seriou
infecti
agent
encount
healthcar
set
categor
rout
transmiss
discuss
initi
assess
test
pep
regimen
advers
effect
followup
test
work
restrict
also
briefli
discuss
primari
prevent
infect
prevent
control
precaut
vaccin
infect
follow
exposur
bloodborn
pathogen
expos
area
immedi
wash
soap
water
cleans
antisept
eg
chlorhexidin
glucon
expos
mucou
membran
flush
copiou
amount
water
eye
irrig
salin
water
risk
factor
baselin
statu
hiv
hbv
hcv
bloodborn
pathogen
assess
sourc
expos
hcp
necessari
test
sourc
patient
statu
hiv
hbv
hcv
known
posit
statu
infect
unknown
histori
medic
record
test
determin
diseas
statu
sourc
expos
hcp
perform
promptli
recommend
test
hepat
b
surfac
antigen
hbsag
hepat
c
antibodi
hiv
antibodi
recommend
test
needl
sharp
instrument
implic
exposur
pep
hiv
hbv
nonimmun
given
hcp
earli
possibl
wait
inform
test
result
exposur
associ
risk
transmiss
howev
hepat
b
vaccin
given
nonimmun
expos
hcp
futur
exposur
risk
even
present
day
exposur
expos
hcp
counsel
modifi
sexual
practic
hiv
avoid
breastfeed
pregnanc
hiv
refrain
donat
blood
plasma
organ
tissu
semen
infect
rule
averag
risk
hiv
transmiss
percutan
mucocutan
exposur
hivinfect
blood
healthcar
set
approxim
three
one
per
exposur
respect
risk
transmiss
hiv
percutan
exposur
hivinfect
blood
increas
deep
injuri
visibl
blood
devic
procedur
involv
needl
arteri
vein
high
hiv
viral
load
low
level
hiv
viral
load
blood
use
antiretrovir
therapi
art
associ
reduct
risk
hiv
transmiss
select
threedrug
regimen
hiv
pep
guid
proven
efficaci
toler
side
effect
toxic
profil
eas
administr
known
suspect
resist
sourc
viru
art
prefer
hiv
pep
regimen
tenofovir
emtricitabin
raltegravir
base
proven
efficaci
treatment
hiv
infect
toler
tabl
hiv
pep
continu
result
hiv
test
avail
sourc
patient
known
confirm
hivinfect
pep
continu
day
hiv
antibodi
test
neg
sourc
patient
pep
discontinu
followup
hiv
test
expos
hcp
requir
howev
sourc
patient
risk
hiv
exposur
previou
week
acut
retrovir
syndrom
clinic
suspect
plasma
hiv
rna
test
recommend
pep
continu
result
plasma
hiv
rna
assay
avail
rapid
hiv
test
recommend
test
util
decisionmak
regard
pep
hiv
statu
sourc
unknown
fourthgener
hiv
antigenantibodi
combin
test
prefer
serolog
screen
test
rapid
hiv
test
posit
followup
test
expos
hcp
posit
hiv
antibodi
test
confirm
supplement
test
antibodi
differenti
immunoassay
expos
hcp
follow
outpati
clinic
day
initi
assess
everi
week
end
pep
treatment
blood
test
tabl
expos
hcp
develop
acut
ill
consist
primari
hiv
infect
febril
mononucleosislik
ill
test
hiv
fourthgener
enzym
immunoassay
hiv
rna
assay
recommend
hiv
antibodi
test
posit
baselin
time
follow
hcp
refer
clinician
experienc
hiv
care
manag
treatment
incid
report
local
health
depart
occup
acquir
risk
hbv
transmiss
percutan
exposur
blood
hbvinfect
patient
approxim
need
type
pep
hbv
base
type
exposur
hbsag
statu
sourc
patient
diseas
statu
expos
hcp
vaccin
statu
vaccinerespons
statu
expos
hcp
tabl
hbv
vaccin
hepat
b
immunoglobulin
effect
prevent
hbv
infect
given
within
hour
exposur
risk
transmiss
hcv
follow
percutan
exposur
blood
hcvinfect
sourc
patient
estim
per
exposur
sinc
effect
pep
regimen
prevent
hcv
transmiss
goal
earli
identif
infect
present
referr
follow
evalu
treatment
option
experienc
clinician
tabl
serum
alanin
aminotransferas
level
elev
follow
hcp
test
hcv
rna
assess
acut
hcv
infect
hcp
becom
acut
infect
hepat
c
immedi
referr
specialist
experienc
treatment
hepat
c
strongli
recommend
primari
prevent
occup
infect
bloodborn
pathogen
achiev
prevent
exposur
blood
bodi
fluid
infect
control
precaut
use
safeti
devic
safer
work
practic
engin
control
improv
surgic
techniqu
educ
hcp
prevent
needlestick
injuri
postexposur
care
vaccin
hbv
hcp
higher
averag
risk
acquir
tuberculosi
tb
particularli
tbpreval
area
estim
latent
tb
infect
ltbi
rate
among
hcp
countri
low
intermedi
high
tb
incid
respect
patient
unrecogn
tb
diseas
promptli
place
appropri
airborn
precaut
major
risk
factor
transmiss
mycobacterium
tuberculosi
healthcar
set
risk
transmiss
higher
follow
contact
patient
cavitari
pulmonari
laryng
tb
acidfast
bacilli
afb
smear
posit
sputum
cough
effect
antitb
treatment
initi
treatment
new
case
infecti
tb
identifi
healthcar
set
contact
prior
implement
infect
control
measur
identifi
evalu
tb
diseas
ltbi
highest
prioriti
contact
evalu
given
hcp
medic
risk
factor
tb
diseas
eg
hiv
infect
immunocompromis
present
aerosolproduc
procedur
eg
bronchoscopi
sputum
induct
autopsi
tabl
hcp
expos
potenti
infecti
tb
sourc
evalu
promptli
symptom
screen
tb
tuberculin
skin
test
tst
releas
assay
igra
tst
igra
perform
expos
hcp
previou
posit
test
result
histori
treatment
ltbi
tb
diseas
tst
igra
symptom
screen
repeat
week
later
initi
tst
igra
result
neg
hcp
asymptomat
repeat
tst
contraind
unless
test
associ
sever
ulcer
anaphylact
shock
case
igra
recommend
test
igra
also
prefer
previous
bacillu
bcg
vaccin
hcp
choic
cut
point
posit
tst
result
exposur
activ
tb
index
case
depend
baselin
tst
result
known
whether
expos
hcp
immunocompromis
condit
prior
bcg
vaccin
statu
use
interpret
tst
set
contact
investig
result
tst
read
design
train
clinician
hour
tst
place
document
millimet
simpli
neg
posit
posit
tst
contact
known
infecti
tb
patient
defin
mm
hcp
previou
tst
result
mm
increas
mm
hcp
previou
tst
result
mm
mm
immunocompromis
hcp
tst
mm
baselin
followup
test
consid
posit
expos
hcp
posit
tst
igra
evalu
screen
symptom
sign
tb
diseas
chest
radiographi
rule
tb
diseas
tb
diseas
rule
treatment
ltbi
consid
treatment
ltbi
significantli
reduc
risk
progress
infect
tuberculosi
tb
diseas
tabl
expos
immunocompromis
hcp
eg
hiv
infect
organ
transplant
evalu
screen
symptom
sign
tst
igra
chestxray
test
normal
start
treatment
ltbi
due
high
risk
develop
activ
diseas
repeat
tst
igra
week
neg
treatment
ltbi
discontinu
clinician
may
choos
complet
treatment
cours
ltbi
situat
sinc
tst
igra
may
reliabl
sever
immunocompromis
condit
expos
hcp
develop
symptom
sign
tb
eg
fever
weight
loss
hemoptysi
follow
chest
xray
afb
smear
cultur
perform
hcp
treat
tb
diseas
indic
prevent
tb
among
hcp
accomplish
educ
regard
tb
symptom
transmiss
prevent
provid
train
proper
don
dof
person
protect
equip
ppe
respir
mask
addit
annual
screen
symptom
sign
tb
diseas
baselin
hcp
low
mediumrisk
set
annual
mediumrisk
set
tb
screen
hcp
neg
tst
igra
treatment
hcp
ltbi
recommend
varicella
caus
varicellazost
viru
vzv
highli
contagi
secondari
attack
rate
transmit
via
direct
contact
vesicl
inhal
aerosol
vesicular
fluid
respiratori
tract
secret
patient
varicella
dissemin
herp
zoster
hz
hz
much
less
contagi
varicella
varicella
still
occur
vaccin
expos
person
infect
usual
milder
less
infecti
unvaccin
one
nosocomi
transmiss
uncommon
usual
due
delay
diagnosi
incorrect
diagnosi
late
implement
infect
control
precaut
pep
regimen
varicella
hz
includ
varicella
vaccin
varicella
zoster
immun
globulin
varizig
oral
antivir
agent
tabl
varicella
vaccin
zoster
vaccin
effect
prevent
varicella
infect
risk
reduct
develop
sever
diseas
due
vaccineinduc
vzvspecif
tcell
prolifer
given
within
day
exposur
index
case
varicella
zoster
diseas
usual
mild
vaccin
person
seroconvert
lost
detect
antibodi
develop
varicella
exposur
vzv
hcp
develop
vaccinerel
rash
avoid
contact
suscept
patient
resolut
rash
varizig
effect
prevent
diseas
modif
varicella
expos
suscept
person
given
ideal
within
hour
day
exposur
note
none
pep
regimen
complet
effect
prevent
diseas
exposur
breakthrough
infect
report
measl
highli
contagi
diseas
secondari
attack
rate
major
measl
case
occur
either
unvaccin
hcp
hcp
unknown
vaccin
statu
still
occur
immun
person
exposur
index
case
measl
vaccin
may
prevent
attenu
sever
diseas
given
within
day
exposur
limit
contact
set
school
childcar
medic
offic
immunoglobulin
product
effect
prevent
modifi
infect
addit
reduc
mortal
person
nonimmun
administ
within
day
exposur
measl
mump
rubella
vaccin
highli
effect
primari
prevent
measl
twodos
vaccin
effect
ebola
infect
caus
ebolaviru
part
famili
filovirida
although
natur
reservoir
host
unknown
viru
transmit
persontoperson
result
outbreak
case
ebola
death
current
outbreak
ebola
west
africa
viru
transmit
direct
contact
broken
skin
mucou
membran
blood
bodi
fluid
tissu
skin
symptomat
infect
patient
person
die
diseas
risk
transmiss
particularli
high
later
stage
infect
viral
load
high
transmiss
possibl
incub
period
patient
asymptomat
hcp
care
ebola
patient
highest
risk
infect
wear
appropri
ppe
unfortun
avail
pep
ebola
expos
hcp
stop
work
immedi
report
occup
health
supervisor
monitor
temperatur
twice
daili
day
last
exposur
report
temperatur
symptomssign
ebola
infect
clinician
follow
updat
inform
avail
center
diseas
control
prevent
world
health
organ
health
organ
websit
postexposur
manag
avian
influenza
middl
east
respiratori
syndrom
coronaviru
summar
tabl
healthcareassoci
sever
group
streptococc
ga
infect
occur
rate
surgic
obstetr
gynecolog
burn
unit
ward
commonli
involv
hospit
outbreak
ga
infect
issu
treat
contact
invas
ga
iga
index
case
debat
unknown
antibiot
therapi
decreas
risk
acquir
ga
infect
gener
agre
pep
routin
given
contact
iga
case
decis
use
pep
contact
base
clinician
assess
risk
associ
hcp
guidanc
local
institut
tabl
hcp
contact
index
case
iga
infect
screen
ga
develop
sore
throat
skin
infect
skin
lesion
vagin
pruritu
within
day
contact
index
case
outbreak
ga
infect
infect
control
depart
may
decid
screen
asymptomat
hcp
ga
screen
ga
perform
throat
skin
lesion
neg
nose
anu
vagina
screen
hcp
found
posit
ga
receiv
antibiot
erad
therapi
tabl
screen
ga
repeat
day
complet
therapi
still
posit
ga
hcp
retreat
household
contact
screen
nosocomi
transmiss
n
meningitidi
rare
due
adher
infect
control
practic
hcp
acquir
organ
contact
respiratori
secret
infect
patient
laboratori
set
antibiot
therapi
use
pep
effect
prevent
infect
exposur
erad
nasopharyng
carriag
n
meningitidi
tabl
quadrival
c
meningococc
polysaccharid
vaccin
conjug
meningococc
vaccin
menacwyd
menacwycrm
protect
diseas
among
adult
induct
detect
bactericid
antibodi
declin
year
postvaccin
meningococc
vaccin
use
routin
vaccin
schedul
highrisk
hcp
tabl
institut
outbreak
defin
occurr
confirm
probabl
primari
case
meningococc
diseas
caus
serogroup
month
outbreak
hcp
vaccin
meningococc
vaccin
contain
respons
serogroup
recent
approv
meningococc
vaccin
serogroup
b
indic
individu
year
age
role
hcp
vaccin
clear
pertussi
highli
contagi
diseas
secondari
attack
rate
may
turn
outbreak
pertussi
communic
first
week
ill
catarrh
earli
paroxysm
stage
transmiss
neglig
week
untreat
infect
day
initi
effect
antibiot
therapi
benefit
pep
expos
hcp
pertussi
well
support
strong
evid
tabl
howev
gener
recommend
unvaccin
hcp
signific
exposur
infecti
patient
given
pep
hand
vaccin
hcp
given
option
either
take
pep
monitor
symptom
day
last
contact
infecti
index
patient
provid
pep
prefer
vaccin
hcp
high
risk
sever
diseas
hcp
work
patient
high
risk
sever
diseas
neonat
pregnant
women
effect
pertussiscontain
vaccin
eg
tetanusdiphtheriaacellular
pertussi
diphtheriatetanusacellular
pertussi
primari
prevent
pertussi
rang
durat
immun
unknown
influenza
larg
burden
healthcar
set
sinc
common
infect
caus
outbreak
sever
respiratori
ill
among
hospit
patient
longtermcar
resid
viral
shed
typic
occur
day
symptom
onset
day
onset
although
young
children
immunocompromis
patient
may
shed
viru
longer
durat
antivir
agent
shown
effect
pep
unprotect
exposur
influenza
particularli
outbreak
situat
howev
concern
antivir
resist
usual
prefer
watch
expos
hcp
initi
treatment
earli
symptom
develop
decid
give
pep
hcp
contact
high
risk
influenza
complic
contact
person
high
risk
influenza
complic
tabl
effect
influenza
vaccin
prevent
influenza
vari
depend
age
health
statu
person
match
circul
strain
strain
includ
vaccin
season
influenza
vaccin
serolog
effect
hcp
vaccin
impact
clinic
ill
among
hcp
contact
well
establish
postexposur
manag
infect
transmit
droplet
rout
summar
tabl
scabi
caus
mite
sarcopt
scabiei
result
mani
outbreak
differ
healthcar
set
scabi
transmit
primarili
skintoskin
contact
infest
person
crust
scabi
million
mite
infest
singl
host
contagi
scabi
transmit
casual
contact
hold
hand
fomit
cloth
linen
pep
given
expos
hcp
lack
sign
infest
case
continu
outbreak
pep
scabi
given
asymptomat
hcp
contact
consult
infect
control
occup
health
depart
tabl
postexposur
manag
infect
transmit
contact
rout
summar
tabl
postexposur
manag
respons
hcp
occup
health
provid
employ
made
possibl
awar
risk
potenti
intervent
exposur
sever
challeng
postexposur
manag
hcp
infecti
sourc
includ
evalu
unknown
sourc
patient
sourc
patient
refus
test
difficulti
determin
level
risk
transmiss
exposur
incid
avail
rapid
diagnost
test
sourc
patient
test
sensit
specif
diagnost
test
disclosur
relat
inform
sourc
individu
unavail
pep
regimen
develop
drugresist
pathogen
eg
tb
adher
expos
hcp
clinic
visit
prescrib
pep
regimen
urgent
need
pep
seriou
infect
hcv
ebola
establish
protocol
postexposur
manag
multidisciplinari
team
approach
access
expert
consult
may
solv
challeng
